Related Experiment Video
Updated: May 27, 2026

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
Published on: July 16, 2021
VCP mutations in familial and sporadic amyotrophic lateral sclerosis
Max Koppers1, Marka M van Blitterswijk, Lotte Vlam
1Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands.
Abstract:
Mutations in the valosin-containing protein (VCP) gene were recently reported to be the cause of 1%-2% of familial amyotrophic lateral sclerosis (ALS) cases. VCP mutations are known to cause inclusion body myopathy (IBM) with Paget's disease (PDB) and frontotemporal dementia (FTD). The presence of VCP mutations in patients with sporadic ALS, sporadic ALS-FTD, and progressive muscular atrophy (PMA), a known clinical mimic of inclusion body myopathy, is not known. To determine the identity and frequency of VCP mutations we screened a cohort of 93 familial ALS, 754 sporadic ALS, 58 sporadic ALS-FTD, and 264 progressive muscular atrophy patients for mutations in the VCP gene. Two nonsynonymous mutations were detected; 1 known mutation (p.R159H) in a patient with familial ALS with several family members suffering from FTD, and 1 mutation (p.I114V) in a patient with sporadic ALS. Conservation analysis and protein prediction software indicate the p.I114V mutation to be a rare benign polymorphism. VCP mutations are a rare cause of familial ALS. The role of VCP mutations in sporadic ALS, if present, appears limited.
Insights
Valosin-containing protein (VCP) gene mutations are a rare cause of familial amyotrophic lateral sclerosis (ALS). This study found VCP mutations play a limited role in sporadic ALS and related disorders.
Area of Science:
- Genetics
- Neurology
Background:
- Valosin-containing protein (VCP) gene mutations are linked to familial amyotrophic lateral sclerosis (ALS), inclusion body myopathy (IBM), Paget's disease of bone (PDB), and frontotemporal dementia (FTD).
- The frequency of VCP mutations in sporadic ALS, sporadic ALS-FTD, and progressive muscular atrophy (PMA) remains unknown.
Purpose of the Study:
- To investigate the prevalence and spectrum of VCP gene mutations in patients with familial ALS, sporadic ALS, sporadic ALS-FTD, and PMA.
Main Methods:
- Genetic screening of VCP gene mutations in a cohort of 93 familial ALS, 754 sporadic ALS, 58 sporadic ALS-FTD, and 264 PMA patients.
- Utilized conservation analysis and protein prediction software to assess mutation pathogenicity.
Main Results:
- Identified two nonsynonymous VCP mutations: a known mutation (p.R159H) in a familial ALS patient with a family history of FTD, and a novel mutation (p.I114V) in a sporadic ALS patient.
- The p.I114V mutation was predicted to be a rare benign polymorphism.
Conclusions:
- VCP mutations are an infrequent cause of familial ALS.
- The contribution of VCP mutations to sporadic ALS and related conditions appears minimal.
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Huntington Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

